Literature DB >> 8486043

Strategy for diagnosis of patients with suspected acute pulmonary embolism.

P D Stein1, R D Hull, H A Saltzman, G Pineo.   

Abstract

STUDY PROTOCOL: Two separate groups of clinical investigators have provided new information and divergent approaches to the management of acute pulmonary embolism (PE). In this position paper, investigators from both groups (Prospective Investigation of Pulmonary Embolism Diagnosis [PIOPED] and Canadian study groups) have utilized the combined scientific database in order to rationalize seemingly polarized diagnostic recommendations into a single practical algorithm.
METHODS: An in-depth review established the relative risks of deep venous thrombosis (DVT) and the related accuracy of diagnostic tests. In PIOPED, 640 of 887 patients at risk for PE had either an intermediate probability ventilation/perfusion (V/Q) scan or a V/Q scan probability that was discordant with the prior estimate of probability by clinical assessment. The risk of PE in these patients was 16 to 88 percent (average, 34 percent). In this group, we calculated the probability of PE assuming that tests for DVT had been performed and that 50 percent of patients with PE have detectable proximal DVT. By calculation, 108 in 640 patients of whom the diagnosis of PE was uncertain, would have shown proximal DVT. In 239 of these 640 patients, tests for DVT would have been negative and the risks of PE in these patients is calculated to be less than 10 percent.
RESULTS: Therefore, we calculate that in 347 of 640 patients, confident recommendations for treatment or no treatment could have been given without pulmonary angiography. Accordingly, in the PIOPED study group of 887 patients, the need for pulmonary angiography would have been reduced from 640 (72 percent) to 293 patients (33 percent).
CONCLUSION: In conclusion, a diagnostic strategy that includes the clinical evaluation, V/Q scan, and evaluation for DVT would decrease the number of patients who require pulmonary angiography from 72 to 33 percent.

Entities:  

Mesh:

Year:  1993        PMID: 8486043     DOI: 10.1378/chest.103.5.1553

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Suspected acute pulmonary embolism: a practical approach. British Thoracic Society, Standards of Care Committee.

Authors: 
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

Review 2.  Anticoagulation therapy for venous thromboembolism.

Authors:  David K Cundiff
Journal:  MedGenMed       Date:  2004-09-09

3.  Deep vein thrombosis and pulmonary embolism - Prevention, management, and anaesthetic considerations.

Authors:  Krishan Kumar Narani
Journal:  Indian J Anaesth       Date:  2010-01

Review 4.  Imaging of suspected pulmonary embolism and deep venous thrombosis in obese patients.

Authors:  Vincent Cascio; Man Hon; Linda B Haramati; Animesh Gour; Peter Spiegler; Sanjeev Bhalla; Douglas S Katz
Journal:  Br J Radiol       Date:  2018-06-27       Impact factor: 3.039

Review 5.  Prevention and treatment of venous thromboembolism.

Authors:  G F Pineo; R D Hull
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

6.  Feasibility, safety and clinical utility of angiography in patients with suspected pulmonary embolism.

Authors:  E J van Beek; J A Reekers; D A Batchelor; D P Brandjes; H R Büller
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

7.  Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

Authors:  T Higenbottam; A Y Butt; A McMahon; R Westerbeck; L Sharples
Journal:  Heart       Date:  1998-08       Impact factor: 5.994

8.  Pulmonary embolism and patent foramen ovale thrombosis: the key role of TEE.

Authors:  Walter Serra; Giuseppe De Iaco; Claudio Reverberi; Tiziano Gherli
Journal:  Cardiovasc Ultrasound       Date:  2007-08-24       Impact factor: 2.062

Review 9.  Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy.

Authors:  Alina Gherasim; Ahn Dao; Jonathan A Bernstein
Journal:  World Allergy Organ J       Date:  2018-11-14       Impact factor: 4.084

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.